Startup Funding

Menu
Subscribe
Search
From Diligence to Discipline: Building an Investment Process That Scales

From Diligence to Discipline: Building an Investment Process That Scales

•
Fundraising, Investing

Related Guides

    Trending

    The most popular articles on Startup Funding in the past day.

    From Diligence to Discipline: Building an Investment Process That Scales

    March 1, 2026

    5 min read From Diligence to Discipline: Building an Investment Process That Scales How to turn subjective deal evaluation into a repeatable, data-informed process across multiple sectors and funds. Every investor starts with instinct. A compelling founder. A trending sector. A deal that “feels right.” But instinct doesn’t scale. As portfolios expand across sectors, stages, and geographies, subjective evaluation becomes inconsistent. One partner underwrites vision. Another prioritizes metrics. A third leans on pattern recognition. Over time, standards drift. Professional investing requires more than diligence. It requires discipline. The firms that outperform don’t just analyze deals. They systematize how analysis happens. Below is a practical framework for turning individual judgment into a structured investment process that scales across teams and funds. 1. Define the Investment Lens Before the Deal Arrives Scaling starts with clarity. Without a defined lens: Evaluation criteria shift mid-process Bias enters quietly Partners debate philosophy instead of facts A scalable process begins with codified principles: Mandate Clarity Sector boundaries Stage focus Check size parameters Risk tolerance profile Return Design Target ownership Power-law assumptions Loss ratio expectations Follow-on strategy If the mandate isn’t precise, screening becomes interpretive. Discipline starts before the first pitch. 2. Standardize Initial Screening Diligence is expensive. Screening is leverage. Before deep analysis, every deal should pass through a consistent first-pass evaluation framework. Core screening pillars: Market Structure Is this market expanding structurally? Is timing accelerating adoption? Competitive Positioning Is differentiation structural or narrative? Does the advantage strengthen with scale? Economic Logic Are unit economics viable at maturity? Does capital efficiency align with fund strategy? Execution Credibility Has this team demonstrated evidence of learning velocity? Each pillar receives a structured score, qualitative inputs, and quantified outputs. The goal isn’t precision. It’s comparability. Across 100 deals, patterns emerge. 3. Convert Judgment Into Scoring Models Subjectivity doesn’t disappear. It gets organized. A scalable investment process translates qualitative insight into structured scoring systems: Weighted evaluation categories Defined scoring thresholds Documented rationale for deviations For example: Market (25%) Defensibility (20%) Economics (25%) Execution (20%) Governance (10%) Each category contains defined sub-criteria. Each sub-criterion includes evidence requirements. This creates: Transparent partner discussions Historical pattern recognition Auditability across funds When analyzing future performance, firms can trace decisions back to structured inputs, not memory. Data accumulates. Insight compounds. 4. Institutionalize Diligence Depth Not every deal deserves the same effort. Scaling firms create tiered diligence levels: Level 1: Screen Deck review 30-minute founder call High-level scoring Level 2: Structured Diligence Market validation Customer references Financial model stress test Cap table analysis Level 3: Investment Committee Independent partner memo Risk articulation Scenario modeling Exit pathway mapping Clear gates prevent over-investment in marginal opportunities. Discipline protects time. 5. Build a Centralized Data Architecture Process scales through infrastructure. Leading firms implement centralized deal tracking systems that capture: Screening scores Diligence notes Market theses Decision outcomes Post-investment performance Over time, this creates: Cross-sector pattern recognition Bias detection Performance attribution analysis Improved underwriting calibration Without historical data, learning remains anecdotal. With structured data, pattern recognition becomes institutional. 6. Separate Excitement From Conviction As firms grow, signaling risk increases: Hot sectors generate internal pressure Competitive rounds compress timelines External validation replaces independent analysis A disciplined process forces: Explicit risk documentation Pre-mortem analysis Return scenario modeling Defined “walk-away” triggers If conviction can’t survive structure, it isn’t conviction. It’s enthusiasm. 7. Align Governance With Process Scaling funds fail when decision authority becomes ambiguous. Institutional discipline requires: Clear IC voting thresholds Documented dissent Defined escalation procedures Post-mortem reviews on both wins and losses Governance turns the process from a suggestion into a standard. It ensures that discipline survives growth. 8. Review the Process, Not Just the Portfolio Most firms review company performance. Few review underwriting performance. Annual process audits should examine: Were top-performing deals high-scoring at entry? Did low-scoring deals outperform expectations? Where did false negatives occur? Did risk flags materialize? Refining filters improves future capital allocation. Scaling isn’t just deploying more capital. It’s improving decision quality over time. Why Discipline Outperforms Pure Diligence Diligence is deal-specific. Discipline is system-wide. Without structure: Standards drift Bias compounds Lessons fade With structure: Evaluation becomes comparable Insights compound Teams align Risk becomes intentional The objective isn’t eliminating uncertainty. It’s creating a repeatable framework that performs under uncertainty—across sectors, across partners, across funds. Final Thoughts From first fund to multi-vehicle platform, the inflection point isn’t capital raised. It’s process maturity. Great investors don’t just refine companies. They refine how they decide. They: Define their lens before the pitch Quantify qualitative judgment Gate diligence intelligently Capture decision data Audit their own thinking Over time, discipline compounds faster than instinct. And that compounding, not individual brilliance, is what builds enduring investment performance. Want access to structured investment scorecards, IC memo templates, and scalable diligence frameworks designed for multi-sector funds? Join our investor community for practical tools that transform subjective evaluation into disciplined, data-informed capital allocation, so your process scales as effectively as your portfolio.

    How to Diligence the Team Behind the Tech

    February 22, 2026

    5 min read  How to Diligence the Team Behind the Tech Assessing leadership readiness, decision velocity, and team adaptability as predictors of scaling success. Technology attracts attention. Code demos impress. Product roadmaps inspire. But companies don’t scale solely because of technology. They scale because of the people making decisions behind it. Professional investors understand this: great technology in the hands of an unprepared team rarely survives growth. Meanwhile, capable leadership can iterate, pivot, and rebuild even when the first product misses. When evaluating early-stage opportunities, diligence is not a soft exercise. It’s a predictive one. Below is a practical framework for assessing leadership readiness, decision velocity, and adaptability, the core traits that determine whether a team can scale what they’ve built. Leadership Readiness → “Are They Built for the Next Stage?” Founders often succeed at starting companies. Scaling them requires a different skill set. Early-stage leadership is about creativity and hustle. Scaling-stage leadership is about structure, delegation, and capital allocation. The key question: Is this team prepared for the company they’re trying to become? Pressure-test: Have they hired executives before, or only individual contributors? Do they understand financial drivers beyond product development? Can they articulate a 12–24-month hiring roadmap tied to milestones? Have they operated through a prior growth phase, or only early formation? Strong readiness signals look like: Clear recognition of their own capability gaps Defined role ownership across leadership Thoughtful sequencing of hires Comfort with accountability and reporting structures Red flag: “We’ll figure out management when we get there.” Scaling punishes improvisation. Leadership maturity reduces operational drag before it compounds. Decision Velocity → “How Fast and How Well Do They Decide?” In scaling companies, speed is a strategic weapon. But speed without judgment is volatility. Decision velocity isn’t just about moving quickly. It’s about moving decisively with incomplete information—and learning from outcomes. Evaluate: How long does it take them to prioritize? Do decisions require consensus—or is authority clear? Can they explain past pivots in terms of logic, not emotion? Do they track the outcomes of major decisions? Strong velocity signals look like: Documented decision frameworks Defined escalation paths Willingness to kill underperforming initiatives Evidence of rapid iteration cycles Red flag: Endless debate disguised as collaboration. Markets move. Competitors adapt. Capital runs out. Teams that cannot decide under uncertainty create internal bottlenecks that stall growth. Scaling companies don’t fail from a lack of ideas. They fail from decision paralysis. Team Adaptability → “Can They Evolve Without Breaking?” Every growth stage introduces friction: New customer segments New compliance requirements New pricing pressures New competitors The team that built version 1.0 may not automatically be the one to build version 3.0. Adaptability is the ability to: Reallocate resources quickly Replace underperforming leaders Adopt new systems Accept external expertise Pressure-test: Have they pivoted before? Did they blame the market, or analyze their own assumptions? Are they coachable? How do they respond to critical board feedback? Strong adaptability signals look like: Transparent post-mortems Iterative roadmap updates Openness to external advisors Recruiting talent stronger than the founders Red flag: Attachment to original vision at the expense of evidence. Technology evolves. Markets shift. Investors change expectations. Teams that treat adaptation as weakness often collapse under scale pressure. Talent Density → “Who Do They Attract?” Strong leaders attract strong operators. Examine: Early key hires, are they high leverage? Retention of top contributors Clarity in organizational design Cultural alignment with performance expectations High-talent teams show: Intentional hiring, not opportunistic Clear performance metrics Fast removal of misaligned hires Leadership depth beyond the founder Red flag: Overreliance on one visionary individual. Scaling requires distributed competence. When decision-making, product insight, and customer relationships concentrate in one person, fragility increases. Alignment Under Stress → “What Happens When Things Go Wrong?” Every scaling journey encounters setbacks: Missed revenue targets Delayed product releases Capital shortfalls The real diligence happens in how teams describe difficult moments. Listen for: Ownership vs. deflection Structured problem-solving vs. emotional reaction Cohesion vs. internal blame Strong stress signals look like: Shared accountability language Clear corrective action plans Data-driven explanations Confidence without denial Red flag: Narrative revisionism. Teams that rewrite history rather than analyze it repeat mistakes at scale. How These Factors Interact Leadership readiness without decision velocity creates bureaucracy. Decision speed without adaptability creates reckless pivots. Adaptability without alignment creates internal churn. Investors aren’t looking for perfection. They’re looking for: Clear growth awareness Defined authority structures Evidence of learning Capacity to recruit beyond themselves Resilience under pressure Technology scales when leadership scales with it. Why Team Diligence Outperforms Product Diligence Products change. Markets evolve. Models iterate. But leadership patterns tend to persist. A disciplined team: Improves weak products Adjusts pricing Finds distribution Raises follow-on capital An undisciplined team: Burns capital faster Creates internal confusion Resists oversight Blames external factors When technology fails, strong teams rebuild. When teams fail, technology rarely saves them. Final Thoughts Diligencing the team behind the tech is not about personality fit or charisma. It’s about operational indicators of scaling readiness. Ask: Are they built for the next stage? Can they decide under uncertainty? Will they adapt when conditions shift? Do they attract and retain talent? Do they hold alignment under stress? The strongest predictors of scaling success are rarely in the demo. They are in the decision patterns, hiring discipline, and leadership maturity of the people running it. Technology may open the door. Leadership determines whether the company walks through it. Want structured team-diligence scorecards, leadership assessment templates, and scaling-readiness evaluation tools used by experienced investors? Join our investor community for practical frameworks designed to help you underwrite teams, not just technology, and invest with greater clarity and conviction.

    The Diligence Playbook for Frontier Innovation

    February 1, 2026

    6 min read The Diligence Playbook for Frontier Innovation Applying structured diligence to emerging technologies—AI, climate tech, biotech—where conventional venture metrics don’t apply. Frontier innovation breaks the rules that traditional venture diligence relies on. There’s little revenue, no clean comps, uncertain regulatory paths, and timelines that don’t fit neatly into SaaS playbooks. Yet capital still has to decide—often earlier, with less signal, and higher consequence. The mistake investors make isn’t backing risky technology. It’s applying the wrong lens of diligence. Great frontier diligence doesn’t try to force certainty where none exists. It replaces standard metrics with structured proof, staged learning, and disciplined risk framing. The goal isn’t to predict outcomes—it’s to understand what must go right, what could break, and whether progress meaningfully reduces uncertainty over time. Below is a practical diligence framework designed specifically for AI, climate tech, biotech, and other frontier domains—where insight matters more than spreadsheets. 1. Frontier Diligence Is About Unknowns, Not Numbers Traditional diligence asks: How fast is this growing? Frontier diligence asks: What don’t we know yet—and how will we find out? These businesses are defined by: Long development cycles Non-linear value creation Technical, regulatory, or scientific risk Markets that may not fully exist yet The core diligence question becomes: Is this team systematically converting uncertainty into knowledge faster than alternatives? Your diligence framework should be built around learning velocity—not short-term performance. 2. Milestone 1: First-Principles Clarity → “Is the Thesis Sound?” Frontier investing starts with intellectual honesty. Objective: Validate that the company’s core insight holds up at a first-principles level. Pressure-test: Why this problem must be solved (not just could be) Why existing solutions fail structurally, not incrementally Why thdoes is approach works given known scientific, technical, or economic constraints Why is now meaningfully different than five years ago Proof looks like: Founders reasoning from fundamentals, not trend narratives Clear articulation of assumptions vs. facts Comfort saying “we don’t know yet” without hand-waving Red flag: Reliance on hype cycles, inevitability arguments, or analogies instead of logic. If the thesis doesn’t survive first principles, no amount of future data will save it. 3. Milestone 2: Technical or Scientific Credibility → “Can This Actually Work?” In frontier tech, feasibility is the first real gate. Objective: Assess whether the underlying technology is plausible—and whether progress is real. Validate through: Independent expert conversations Technical artifacts (models, data, lab results, benchmarks) Roadmaps that acknowledge known hard problems Clear distinction between prototype, proof-of-concept, and production readiness Proof looks like: Evidence of real experimentation, not just simulations Thoughtful tradeoffs (accuracy vs. cost, speed vs. safety, scale vs. reliability) Founders who understand failure modes as deeply as success cases Green flag: Teams that proactively explain what would falsify their approach. This stage isn’t about being right—it’s about being rigorous. 4. Milestone 3: Early Signal of Pull → “Does the World Want This?” Frontier startups often lack customers—but they shouldn’t lack signal. Objective: Identify real-world demand indicators before full product maturity. Signals may include: Pilots, LOIs, or research partnerships Regulatory engagement or early approvals Strategic interest from incumbents Willingness of partners to commit time, data, or resources Proof looks like: External parties taking non-trivial risk or effort Clear articulation of who cares first vs. later Understanding of adoption barriers, not just end-state value Red flag: “Everyone will want this eventually” with no prioritization. Early signal isn’t about revenue—it’s about commitment. 5. Milestone 4: Team Capability Under Ambiguity → “Can They Navigate the Unknown?” Frontier companies don’t execute roadmaps—they navigate fog. Objective: Evaluate whether the team can make high-stakes decisions with incomplete information. Assess: How decisions were made when data was missing How the team integrates new evidence and changes course Role clarity between technical, commercial, and operational leaders The founder’s ability to balance conviction with adaptability Proof looks like: Documented pivots driven by learning, not panic Clear prioritization despite competing uncertainties Leaders who can translate complexity for non-experts Red flag: Overconfidence masquerading as vision. In frontier innovation, judgment beats experience. 6. Milestone 5: Capital as a Learning Instrument → “Does Money Reduce Risk?” Capital should accelerate insight—not just extend runway. Objective: Ensure funding is tied to concrete de-risking milestones. Underwrite: How capital maps to specific unknowns being resolved Whether milestones create option value (more paths forward) Realistic timelines for technical, regulatory, or market inflection points Downside scenarios if assumptions fail Proof looks like: Milestone-driven use of funds Clear criteria for the next fundraising or strategic decisions Willingness to kill paths that don’t work Green flag: Founders who view capital as fuel for learning, not validation. 7. Define Decision Gates Up Front—Especially When Metrics Are Fuzzy Ambiguity without structure leads to endless diligence. Before engaging deeply, align on: What would invalidate the thesis? What evidence is sufficient for this stage? Which risks are acceptable now—and which are not? This prevents: Perpetual “one more question” cycles Moving conviction thresholds Founder exhaustion Frontier diligence must feel disciplined, even when outcomes aren’t. Final Thoughts Frontier investing isn’t about certainty—it’s about earned belief. The best investors don’t pretend to know the future. They: Identify the right unknowns Fund teams that learn faster than competitors Structure diligence to surface trthe uth early When done well: Complexity becomes navigable Risk becomes intentional Conviction becomes defensible Frontier innovation rewards those who replace metrics with judgment—and judgment with process. Want a diligence framework built for AI, climate tech, biotech, and other frontier domains? Join our investor community to access frontier-specific diligence playbooks, technical evaluation guides, and milestone-based decision templates—designed to help you underwrite uncertainty with clarity, discipline, and confidence.

    How to Diligence a Deal Beyond the Deck

    December 14, 2025

    10 min read How to Diligence a Deal Beyond the Deck A practical framework for investors to go deeper than the pitch—focusing on risk domains, capital discipline, and founder transparency. Pitch decks are designed to persuade, not to fully inform. They highlight upside, compress complexity, and often gloss over risk. For investors, relying on the deck alone is one of the fastest ways to misprice risk and overestimate execution. Whether you’re an angel investor, family office, strategic, or venture fund, diligence on a deal beyond the deck requires a structured, skeptical, and evidence-driven approach. The goal isn’t to kill deals to build conviction by understanding where things can break and whether the team has the discipline to navigate those risks. Below is a practical framework to go deeper than the pitch and evaluate a company across its true risk domains. 1. Business Model Clarity & Unit Economics   a. How the Company Actually Makes Money Start by stress-testing the revenue model—not the TAM slide. Ask: Is revenue transactional, recurring, usage-based, or contract-driven? Who is the buyer vs. the end user? What triggers revenue recognition? Break down cost drivers: COGS or service delivery costs Sales commissions and customer success Infrastructure, tooling, or third-party dependencies Look for: Clear margin expansion logic Evidence that costs decline with scale, not just assumptions If unit economics don’t work at a small scale, they rarely work later. b. LTV, CAC, and Payback Reality Founders often present optimistic LTV/CAC ratios. Your job is to pressure-test them. Validate: CAC by channel (not blended averages) Sales cycle length by customer segment Retention, expansion, and churn assumptions Ask: How long does it take to recover CAC on a cash basis? What happens to CAC as the company scales? Are early customers representative—or exceptions? c. Pricing Power & Market Sensitivity Understand whether pricing is: Cost-plus Value-based Competitive or commoditized Test: What happens if prices drop 20%? Can customers easily switch? Is pricing driven by ROI, urgency, or convenience? Real businesses survive pricing pressure. Fragile ones don’t. 2. Risk Domains: Where the Business Can Break Great diligence maps risk before upside. Key risk domains to assess: Market risk (is the problem real and urgent?) Product risk (does it work as claimed?) Execution risk (can the team deliver?) Financial risk (capital sufficiency and burn discipline) Regulatory or compliance risk (if applicable) Dependency risk (customers, vendors, platforms) Ask founders directly: “What are the top three things that could kill this company?” How they answer matters as much as what they say. 3. Product Reality vs. Product Narrative   a. Product-Market Fit Evidence Look for proof—not promises. Validate through: Customer usage data Retention and engagement metrics Pilot-to-paid conversion rates Reference calls with real users Red flags: Heavy roadmap focus with light customer evidence Features driving excitement but not retention “Design partners” that never convert b. Roadmap Discipline A strong roadmap is prioritized, resourced, and sequenced. Ask: What gets built next—and why? What’s customer-driven vs. founder-driven? What milestones unlock revenue or margin? Avoid teams chasing breadth before depth. 4. Go-to-Market Execution   a. Sales Motion Fit Evaluate whether the GTM motion aligns with the product and the buyer. Assess: Self-serve vs. sales-led vs. enterprise Founder-led sales dependency Channel vs. direct strategy Red flags: Long enterprise cycles without a capital runway Complex sales motions with junior teams No clear ICP definition b. Pipeline Quality Inspect pipeline health—not just top-line numbers. Look for: Stage conversion rates Deal slippage patterns Customer concentration risk One “logo” does not equal traction. 5. Founder Transparency & Integrity This is where diligence moves from analytical to judgment-based. Strong founders: Share bad news early Acknowledge weaknesses Provide clean, consistent data Don’t over-defend assumptions Watch for: Shifting answers across meetings Overly polished responses to hard questions Resistance to data requests Trust is built through consistency under pressure. 6. Team & Execution Capacity   a. Role Coverage Evaluate whether critical functions are owned: Product Sales Operations Finance Early-stage teams don’t need depth everywhere—but they need awareness of gaps. b. Execution Track Record Ask: What milestones were hit late—and why? Where has the team over- or under-estimated? How do they course-correct? Past execution is the best predictor of future execution. 7. Financial Discipline & Capital Strategy   a. Burn vs. Learning Healthy burn drives learning and de-risking—not just growth optics. Assess: Monthly burn vs. milestone progress Headcount growth vs. productivity Spend aligned to key risks   b. Capital Plan Reality Understand: How long does the current capital last What milestones justify the next raise Downside survival scenarios Ask: “If fundraising takes 6 months longer than expected, what happens?” 8. Cap Table & Incentive Alignment Review: Ownership distribution SAFEs, notes, and preference stacks Employee option pool health Red flags: Overcrowded early cap tables Misaligned investor rights Founder dilution that kills motivation 9. Market Context & Competitive Positioning Map: Direct competitors Indirect substitutes Incumbent responses Assess: Switching costs Differentiation durability Speed of competitive response Winning often depends on timing, not just product quality. 10. Exit Logic & Investor Fit   a. Plausible Exit Paths Ask: Who buys companies like this? At what scale? On what metrics? Hope is not a strategy, exits follow patterns. b. Alignment Check Finally, assess: Time horizon fit Risk tolerance alignment Strategic vs. financial expectations A good deal for someone else can be a bad deal for you. Final Thoughts Diligencing a deal beyond the deck is about discipline, curiosity, and humility. It means resisting the story long enough to examine the structure underneath—and deciding whether the risks are known, manageable, and worth taking. By applying a structured framework, grounded in unit economics, risk domains, founder transparency, and capital discipline, you move from guessing to conviction. The best investors don’t avoid risk. They understand it better than anyone else in the room.   Hall T. Martin is the founder and CEO of the TEN Capital Network. TEN Capital has been connecting startups with investors for over ten years. You can connect with Hall about fundraising, business growth, and emerging technologies via LinkedIn or email: hallmartin@tencapital.group

    How to Diligence a Cleantech Firm

    December 7, 2025

    7 min read How to Diligence a Cleantech Firm Diligence for a cleantech firm requires a different lens than for traditional software, CPG, or marketplace investing. Whether you’re an angel investor, family office, strategic, or VC, evaluating a cleantech business means examining technology readiness, regulatory compliance, unit economics, carbon impact, capital intensity, and infrastructure dependencies. Here’s a structured, risk-aware playbook to diligence a cleantech company with confidence. 1. Understand the Business Model & Unit Economics   a. Revenue Model & Cost Structure Determine whether the company generates revenue through hardware sales, SaaS layers, project development, installation contracts, or long-term service agreements (e.g., O&M or energy-as-a-service). Break down COGS: components, engineering labor, installation, freight, commissioning, and warranty obligations. Ask how margins improve with volume: Are hardware components commoditized or proprietary? Do economies of scale significantly reduce manufacturing costs? Are service contracts profitable over their lifecycle? b. Lifetime Value (LTV) & Customer Acquisition Costs (CAC) For enterprise or municipal customers: What is the expected contract term? How often do customers expand deployments? What is the churn for service agreements? For residential solutions (e.g., solar installers, battery providers): Evaluate gross profit per project. Compare customer lifetime profit to CAC and installation labor costs. c. Pricing Strategy How price-sensitive is the market? Does the company compete on cost savings, performance, or sustainability ROI? How do market incentives (tax credits, grants, utility rebates) affect pricing? Ensure the pricing model remains viable even if subsidies decrease or competition intensifies. 2. Technology Readiness & Scalability Risks   a. Technology Validation (TRL Levels) Assess technology readiness: Has it been lab-validated, pilot-tested, or commercially deployed? Request: Independent validation reports Performance data Warranty or reliability metrics Identify any unproven assumptions that could hinder commercialization. b. Manufacturing & Supply Chain Where and how is the product manufactured? In-house, outsourced, or contract manufacturing? Are critical components single-source (e.g., rare earth metals, lithium cells)? Evaluate supply-chain resiliency: Lead times Supplier diversification Exposure to geopolitical risk c. Scalability Constraints Does scaling require: Large capex investment? Specialized labor? Utility interconnection approval? Local permitting or environmental assessments? Assess whether physical constraints—not just demand—could limit growth. 3. Market & Go-to-Market Strategy   a. Target Market & Adoption Curve Who are the customers—utilities, industrials, municipalities, real estate developers, corporates, or consumers? Analyze: Market size Market fragmentation Regulatory tailwinds (e.g., IRA incentives, net metering policy) Determine if the market is ready for the solution or if customer education will slow sales cycles. b. Sales Model & Distribution Is the company using direct sales, channel partners, installers, EPCs, or distributors? For enterprise or government sales: Review sales cycle length Contract structure RFP dependency Proof of traction with anchor customers c. Customer Proof & Brand Positioning Evaluate customer testimonials, commercial pilots, and measurable outcomes (e.g., kWh reduction, CO₂ saved, O&M savings). Assess whether the company’s differentiation—performance, sustainability, cost savings, or reliability—is real and defensible. 4. Regulatory, Policy & Compliance Considerations   a. Certifications & Safety Request certification documents such as: UL, CE, ISO standards Grid interconnection compliance (e.g., IEEE standards) Environmental or emissions certifications Check whether the product has undergone third-party testing. b. Policy Dependencies Many cleantech firms depend on incentives. Understand: How the business performs with and without subsidies Risks from policy changes Exposure to tariffs, import duties, or trade restrictions c. Permitting, Interconnection & Local Regulations For grid-dependent products: Interconnection timelines Utility approval processes Permitting risks For environmental tech: EPA, state-level environmental regulation Potential liabilities (e.g., waste handling, emissions compliance) 5. Product & Innovation Pipeline   a. Product-Market Fit Review pilot results, customer feedback, reliability metrics, uptime rates, and warranty claims. Evaluate whether early adopters are becoming long-term customers, and whether the product delivers measurable ROI. b. R&D Roadmap Ask for: Pipeline of next-gen technology Development timelines Budget allocation between R&D and commercialization Intellectual property strategy (patents, trade secrets) Request evidence of technical milestones, not just conceptual roadmaps. c. Competitive Moats Assess whether the company’s innovation is defensible through: Patents Proprietary materials or algorithms Exclusive supply agreements Data advantages High switching costs 6. Team & Operational Execution   a. Founding Team & Technical Expertise Do founders have expertise in energy, engineering, sustainability, hardware, or manufacturing? Have they brought physical technology to market before? b. Organizational Strength Examine structure across engineering, operations, sales, installation, and regulatory functions. Evaluate whether the company has: Solid program/project management Scalable operational processes Strong supply chain and field operations teams c. Execution Metrics Request KPIs such as: Deployment timelines Installation costs Uptime and reliability metrics Warranty claim rates On-time delivery and backlog status Look for signs of operational discipline like documented SOPs and audited processes. 7. Financials & Capital Structure   a. Historical Financials Request: 2–3 years of financial statements Cash flow breakdown (critical for capex-heavy firms) Gross margin trends Equipment and installation cost data Assess whether the company’s growth justifies its burn rate. b. Financial Model & Scenarios Review projections with a focus on: Unit economics under scale Sensitivity to commodity prices Capex requirements for growth Working capital needs (especially for hardware) Installation labor availability Model downside cases: What if incentives drop, cost of materials rises, or deployment slows? c. Cap Table & Funding Requirements Request a detailed cap table including SAFEs, notes, and options. Understand: Existing investor rights Liquidity preferences Future capital needs and dilution risk Dependency on project financing or credit facilities 8. Customer Validation & Market Risk   a. Customer References Speak with customers in pilot or commercial deployments. Ask: Did the technology meet expectations? Was the installation smooth? Did it generate real cost or carbon savings? Would they expand usage? b. Competitive Landscape Map direct and indirect competitors: Incumbents Emerging cleantech startups Cross-category substitutes (e.g., batteries vs. thermal storage) Assess defensibility and switching costs. c. Infrastructure & Channel Risk Evaluate dependencies such as: Utility approval cycles Installation labor availability Supply chain bottlenecks Dependence on one large customer or geographic region 9. ESG, Sustainability & Risk Management   a. Environmental Impact Request lifecycle analyses or carbon footprint data. Verify claims around emissions reduction, recyclability, and energy savings. b. Resilience &

    How to Diligence a Medical Device Startup

    November 30, 2025

    min read How to Diligence a Medical Device Startup How to Diligence a Medical Device Startup A comprehensive investor guide to evaluating clinical value, regulatory risk, and commercialization potential Medical device startups operate within one of the most complex innovation categories, requiring mastery across engineering, clinical medicine, regulation, manufacturing, and reimbursement. For investors, diligence on these companies requires a structured, evidence-based approach that goes far beyond the pitch deck. This guide outlines how to properly diligence a medical device startup, integrating core industry frameworks, regulatory expectations, and the milestone roadmap unique to medtech innovation. Key content to highlight essential metrics, timelines, and development paths. 1. Clinical Problem & Unmet Need Every strong medical device startup begins with a validated, painful clinical problem. The most investable solutions are those that clearly improve outcomes, reduce complications, save clinician time, or reduce healthcare costs. Diligence Questions Is the problem clinically significant and supported by evidence Is the startup solving a proven, unmet need, or is it simply a “nice-to-have”? Does the device fit naturally into a clinician’s workflow? Evidence to Request Peer-reviewed publications Interviews with clinicians (surgeons, nurses, technicians) Hospital pilot interest or letters of support Workflow analysis Clinical validation is not optional; investors should look for early signs that the device will be accepted in practice. 2. Technology, Engineering Maturity & IP Investors must evaluate whether the technology is real, reliable, and defensible. Key Areas to Diligence Prototype functionality (bench testing, usability testing) Software validation (IEC 62304) Human factors engineering (IEC 62366) Reliability and failure mode testing Freedom-to-operate and patent filings Prototypes vs. Clinical Units Prototypes → used for engineering tests and early feedback Clinical unit → the version intended for formal clinical testing Investors should verify that the startup understands and is progressing toward an actual clinical unit, not just a lab prototype. 3. Regulatory Pathway, Risk Class, & Key Metric The regulatory pathway defines cost, timeline, risk, and capital needs. Misjudging it is one of the most common investor mistakes. Your One Key Metric: 510(k) Cycle Time For medical device startups, the key performance metric is not revenue, but rather: Cycle Time Through the 510(k) Application and Approval Process Why? A medical device cannot generate revenue until it receives FDA clearance. The 510(k) process exists to demonstrate that the device is at least as safe and effective as a predicate device already on the market. The typical cycle time ranges from: 50–300 days, depending on device complexity. Investors should ask the startup: What is the standard cycle time for comparable devices? How are you benchmarking against that? What regulatory consultant or QA/RA firm is guiding your path? Understanding this timeline is essential to evaluating execution risk and funding needs. 4. Clinical Evidence, Validation & Trials Investors must examine whether the startup is producing the right evidence at the right time. Core Stages of Clinical Validation Preclinical validation – Initial safety and bench/animal tests First-in-human tests – Early clinical study Clinical validation – Broader human clinical trial data Evidence to Request Cadaver/animal study results Human factors reports Early feasibility human data Biocompatibility and electrical safety testing Strong startups demonstrate a clear, statistically powered plan for pivotal clinical trials, including sites, budget, endpoints, and timeline. 5. Manufacturing, Quality Systems & Supply Chain A medtech startup must eventually scale hardware manufacturing, a central diligence area many investors overlook. Diligence Checklist Design for manufacturability (DFM) Supplier qualification Sterilization pathway and validation Packaging and shelf-life testing ISO 13485-aligned quality management system Without proper QMS and design controls, FDA clearance and manufacturing scale become extremely risky. 6. Reimbursement Strategy & Commercial Model Even with FDA approval, a device can fail commercially without reimbursement. Key Reimbursement Questions Is there an existing CPT, HCPCS, or DRG code? Will a new code be required? What is the economic value to hospitals and providers? Are early health economic studies underway? Strong startups can demonstrate real cost savings or efficiency improvements that justify purchasing. 7. Team, Advisors, & Capital Strategy Execution in medtech requires multidisciplinary excellence. What to Look For Founders with clinical or engineering depth Regulatory and quality expertise Key opinion leaders (KOLs) involved early Experience with device commercialization Capital Planning Medical device development often requires three to five years to reach FDA clearance and initial sales. Investors should verify: Milestone-based fundraising strategy Clear runway aligned to regulatory events. Transparent burn projection 8. The Medical Device Roadmap: A Critical Diligence Tool Medical Device Startup Roadmap Market requirements Product requirements Prototypes Clinical unit Preclinical validation First-in-human test Clinical validation CE Mark (Europe) First European orders 510(k) clearance (US) First US orders Break-even Growth and scale Why this matters for diligence Investors should map the startup’s current stage against this roadmap to evaluate: How far they’ve progressed Whether they are ahead or behind industry norms Whether capital needs align with upcoming milestones What risks remain before revenue is possible This roadmap provides a clear, standardized structure for evaluating readiness and execution risk. Common Red Flags During Diligence No predicate identified for 510(k) No regulatory consultant engaged Confusion between intended use and indications for use Only early prototypes, no pathway to a clinical unit Unrealistic regulatory timelines Limited or no clinical advisor involvement Weak or nonexistent reimbursement plan Underestimation of hospital sales cycles (12–24 months) Diligencing a medical device startup requires a holistic approach that integrates: Clinical need Technology maturity Regulatory strategy 510(k) cycle-time metrics Clinical validation Manufacturing readiness Reimbursement viabilit Team capability Roadmap alignment Capital planning By using these frameworks, especially the medical device roadmap and the 510(k) cycle time regulatory metric, investors can distinguish between a promising concept and a fundable medtech venture capable of achieving clinical and commercial success. Read More from TEN Capital Education here. Hall T. Martin is the founder and CEO of the TEN Capital Network. TEN Capital has been connecting startups with investors for over ten years. You can connect with Hall about fundraising, business growth, and emerging technologies via LinkedIn or email: hallmartin@tencapital.group

    How to Diligence a Therapeutic Startup

    November 15, 2025

    7 min reading How to Diligence a Therapeutic Startup “In therapeutic investing, the science must be right, but the strategy must be smarter.” Diligencing a therapeutic startup is unlike any other form of early-stage investing. It requires balancing scientific rigor with business realism. From molecule to market, investors must evaluate not just whether the science works, but also whether the pathway to revenue and, eventually, to exit is both capital-efficient and strategically defensible. In this article, we distill insights from Startup Funding Espresso episodes on diligence, biotech assessment, and founder fit to create a structured playbook for investors, founders, and diligence teams navigating therapeutic innovation. The Purpose of Diligence Therapeutic startups operate at the intersection of science, regulation, and capital markets. The goal of diligence is to validate alignment across three domains: Technical feasibility — Does the underlying science or technology platform hold up under scrutiny? Regulatory viability — Is there a clear pathway through the FDA, EMA, or equivalent agencies? Commercial potential — Is the market large enough, accessible enough, and ready enough to support sustained adoption? The episode “Setting up Due Diligence” underscores that diligence is not a checklist but a risk-reduction process. Each layer, technical, market, financial, and team, reveals not only what’s known but also where uncertainty resides. Key Pillars of Therapeutic Diligence Across episodes like “What Investors Look for in a Biotech Startup”, “Core Skills for Biotech Drug Development”, and “Best Practices for Therapeutic Startup Fundraising,” five diligence pillars consistently emerge: a. Scientific Validity Evaluate the mechanism of action and supporting pre-clinical data. Look for peer-reviewed validation or collaborations with credible institutions. Avoid overreliance on early, non-replicated studies. b. Regulatory Readiness Determine if the company understands its regulatory classification (drug, biologic, device, or combination product). The episode “Key Documents for Your Due Diligence Box” reminds investors to confirm the presence of pre-IND or pre-submission feedback and a mapped timeline to key milestones (IND, Phase I/II/III, etc.). c. Intellectual Property Strong IP defines competitive durability. Diligence teams should verify patent ownership, freedom-to-operate analyses, and upcoming expirations. The episode “Red Flags in Due Diligence” lists weak patent coverage and licensing ambiguity as common deal-killers. d. Market and Reimbursement The episode “How to Diligence the Market” highlights the importance of mapping addressable markets, reimbursement codes, and pricing elasticity early. In therapeutics, the buyer is often not the user; understanding payer dynamics is as critical as clinical efficacy. e. Team and Execution From “How to Diligence the Team” and “How Much Diligence to Run on a Founder,” we learn that successful therapeutic founders combine scientific depth with regulatory and commercial literacy. Look for balanced teams, scientific founders complemented by business operators and regulatory veterans. Evaluating the Science: From Discovery to Translation Scientific diligence is both art and analytics. The episodes “Technical Due Diligence” and “Performing Due Diligence Like a VC” emphasize reviewing: Preclinical data integrity (sample sizes, control design, statistical significance). Translational relevance (animal model to human trial correlation). Scalability of the therapeutic platform (manufacturing, formulation, delivery). Replicability and documentation quality. The diligence process should involve external subject-matter experts who can assess biological plausibility and experimental design. Investors often underestimate how manufacturing complexity and stability testing can become multi-million-dollar bottlenecks post-Series A. Regulatory Diligence: Navigating the FDA Maze Episodes like “Due Diligence: The Thorough Approach” and “Signing NDAs in Due Diligence” note that regulatory diligence is not just about confidentiality; it’s about clarity. Investors should verify: Has the company engaged with the FDA through pre-IND or Q-submission meetings? Does the clinical plan align with regulatory precedent? Are timelines and budgets realistic given the required studies? For devices and diagnostics, the 510(k), De Novo, and PMA pathways drastically change time-to-market and capital requirements. For drugs, investors should validate the clinical endpoints that regulators will recognize and the CMC (Chemistry, Manufacturing & Controls) readiness. Market Validation and Adoption Risk The episodes “How to Perform Marketing Due Diligence” and “The Role of Social Media in Due Diligence” remind us that even brilliant therapies fail if they can’t cross the commercial chasm. Critical diligence questions include: Who pays for this therapy—patients, insurers, or hospitals? What’s the comparative cost versus the current standard of care? How do KOLs (Key Opinion Leaders) view the therapeutic value? Savvy investors go beyond market sizing they look for evidence of early traction, like investigator interest, LOIs from clinics, or grants validating unmet needs. Financial and Risk Diligence In “Financials, Team and Domain Diligence” and “Going Through Due Diligence,” Hall T. Martin highlights the need to align scientific milestones with capital tranches. Key insights include: Link fundraising to de-risking events (e.g., IND submission, Phase I completion). Assess capital efficiency: how much per data point? Model downside scenarios: what happens if the lead candidate fails? Therapeutic startups should demonstrate clear cash-to-value conversion, showing how each dollar accelerates the next stage of validation. Qualitative and Quantitative Diligence From “The Quantitative and Qualitative Side of Due Diligence,” effective investors integrate metrics and intuition. Quantitatively, they evaluate market size, runway, and clinical timelines. Qualitatively, they examine founder motivation, transparency, and resilience. The best diligence blends data with discernment; a founder’s honesty in disclosing failed experiments often signals stronger integrity than perfect slides. Common Red Flags Episodes like “Red Flags in Due Diligence” and “What Isn’t Being Said in Due Diligence” reveal recurring warning signs: Overstated preclinical results or missing negative data. Lack of clarity on IP ownership or licensing. Unrealistic regulatory timelines. Founders are resistant to third-party validation. Weak capitalization structure or unrecorded convertible debt. Any one of these can indicate a lack of maturity in governance or readiness for institutional investment. Building the Due Diligence Box The “Key Documents for Your Due Diligence Box” episode lists must-have files: Executive summary and pitch deck Scientific white papers IP portfolio summary Regulatory correspondence Financial model and cap table Team bios and advisory board profiles For therapeutics, include clinical protocol summaries and manufacturing validation reports. Organizing these early signals professionalism and preparedness. Performing Diligence Like a VC In “Performing Due Diligence Like a VC,” the guidance

    How to Diligence a Marketplace Startup

    November 9, 2025

    10 min read How to Diligence a Marketplace Startup The Hidden Complexity of Marketplace Investing Marketplace startups look deceptively simple—connect buyers and sellers, take a transaction fee, and scale. Yet beneath the surface lies one of the most intricate business models in venture capital. Each marketplace comprises three intertwined systems: supply acquisition, demand generation, and transaction trust. Diligencing such a company requires investors to look beyond vanity metrics and into the structural mechanics that sustain the network. Unlike SaaS or product companies, a marketplace’s moat emerges not from technology alone but from network density, unit economics, and behavioral liquidity. Accurate diligence measures how these forces interact over time—not just whether the platform is growing, but whether it is compounding. 1. Market Definition and Network Dynamics Total Addressable Market (TAM) and Fragmentation Start with clarity on the target market’s size and fragmentation. The best marketplaces often enter highly fragmented, inefficient markets where incumbents lack digital coordination, such as real estate agents, local services, or niche B2B verticals. A large TAM alone isn’t enough; investors should assess whether participants are ready for platformization. Markets with strong offline incumbents or regulatory friction may resist the shift. Ideal markets have: Many small, independent providers have poor discovery tools. High-frequency transactions that encourage repeat use. A clear “pain point” in finding, vetting, or paying counterparties. Two-Sided Liquidity: Solving the Cold Start Problem The cold-start problem — how to attract both sides of the market simultaneously — is the defining risk for early marketplace ventures. During diligence, look for tactical liquidity strategies: Single-vertical focus: Does the company start narrow to seed density before expanding? Demand priming: Are they subsidizing one side (often the supply side) until cross-traffic builds? Community seeding: Is there an existing user base or offline network that can be digitized quickly? Early liquidity in even a small segment signals the flywheel potential that investors prize. 2. Business Model and Unit Economics Revenue Model Fit The most common monetization models include take rates (transaction fees), subscription tiers, and lead-generation fees. Each implies different risk structures. Transaction fees require trust, and an integrated payment is high-value but high-friction. Subscription models indicate recurring revenue but can mask low transaction activity. Lead models work early but limit scalability once competition rises. Investors should ask: Is the monetization aligned with the core user value? A mismatch between value creation and value capture, like charging suppliers before buyers exist, can choke early growth. Economics per Transaction Healthy marketplaces exhibit a positive contribution margin once acquisition costs normalize. During diligence, evaluate: Take rate vs. CAC: Does the average customer transaction justify the acquisition cost? Repeat usage: Is retention improving as users deepen engagement? Cohort profitability: Do earlier cohorts improve over time (a sign of compounding trust)? An investor-grade model includes LTV/CAC ratios above 3x, declining CAC, and evidence that organic or referral traffic is growing faster than paid channels. 3. Supply and Demand Validation Supply-Side Diligence Strong supply is the backbone of marketplace liquidity. Look for evidence of supply stickiness: Contracts, integrations, or switching costs that prevent churn. Platform tools that embed suppliers’ inventory management, CRM, and analytics. Precise segmentation of high-value vs. low-value suppliers. Investors should scrutinize how supply quality is maintained at scale. The best marketplaces curate, not just aggregate through reputation systems, ratings, or algorithmic filtering. Demand-Side Diligence Demand validation is equally critical. Look for signals of habitual usage: Percentage of users completing transactions vs. browsing. Repeat rate within 30–90 days. Conversion from search to transaction. If acquisition is primarily through paid channels, ask whether organic channels (SEO, referrals, word of mouth) are growing. A healthy marketplace eventually “earns” its traffic through brand trust and liquidity, not just ad spend. 4. Trust, Safety, and Transaction Infrastructure Trust is the invisible currency of marketplaces. Investors often underestimate the importance of dispute resolution, escrow systems, and user verification. Diligence questions to ask: How does the platform mitigate fraud or low-quality interactions? Is there buyer and seller verification? How quickly are disputes resolved? What share of GMV occurs on-platform versus off-platform? A marketplace with a strong safety reputation accelerates network effects. Each satisfied user adds both volume and confidence to future participants. 5. Technology, Data, and Defensibility Technology as an Enabler, Not the Moat While marketplaces are technology-enabled, their defensibility lies more in data loops than in code. Assess: Proprietary matching algorithms or dynamic pricing systems. Unique datasets built from repeated transactions. Predictive analytics is improving the balance between supply and demand. Technology amplifies the moat once scale is achieved, but rarely substitutes for it. Diligence should confirm that technology shortens the distance between intent and transaction. Network Effects and Switching Costs Ask: Do more users make the platform better for all participants? Are switching costs increasing (data lock-in, reputation scores, embedded tools)? Is there evidence of local network effects, city-by-city or niche-by-niche density? True network effects are measurable: declining CAC, improving retention, and rising transaction frequency as density grows. 6. Regulatory and Operational Risks Marketplaces often enter semi-regulated sectors (transportation, healthcare, finance). Investigate compliance exposure early: Licensing or labor classification risks (e.g., gig economy). Data privacy or payment compliance (PCI, GDPR). Local versus national jurisdiction variance. Operational diligence should review internal controls—how the company handles disputes, refunds, and payment reconciliation. Hidden liabilities here can erode margins later. 7. Team, Culture, and Execution Capability In marketplaces, execution discipline matters as much as vision. Founders must balance product growth with operational rigor. Red flags include: Overemphasis on growth without tracking unit economics. Weak analytical culture or reliance on anecdotal success stories. Lack of expertise in supply-chain or logistics for physical marketplaces. Green flags include: Founders who deeply understand both sides of the market. Clear frameworks for scaling liquidity (e.g., city rollout models). Experienced data and operations leadership. Diligence should include references and operator interviews with those who have scaled networks before, as they are rare and invaluable. 8. Investor Fit and Exit Pathways Investors must map the marketplace’s growth to their own fund model. Marketplaces can deliver large exits but often require long gestation periods before compounding effects take hold. Key investor diligence checkpoints: Time to liquidity: Are transaction volumes doubling

    How to Diligence a Deeptech Startup

    November 9, 2025

    5 min read How to Diligence a Deeptech Startup Deeptech investing sits at the frontier of science and innovation where research, engineering, and commercialization intersect. Unlike pure software startups, deeptech ventures build defensible advantages through hard science: novel materials, AI hardware, quantum systems, robotics, medtech, or energy storage breakthroughs. These opportunities are exciting but also carry unique risks. Traditional venture diligence frameworks often fall short when technology readiness, regulatory hurdles, and manufacturing scalability dominate the risk stack. This article distills key lessons from Startup Funding Espresso episodes on diligence, technology risk, and commercialization. The goal: to help investors and founders apply a structured, evidence-based approach to evaluating deeptech startups. Why Deeptech Diligence Is Different Every deeptech company compresses three risk domains—science, engineering, and market adoption into a single domain. The challenge is not just whether the technology works, but whether it can be built repeatedly, validated independently, and sold at scale. Traditional diligence focuses on traction and market fit; deeptech diligence begins earlier, with proof-of-concept data, IP defensibility, and regulatory feasibility. Investors must verify not only what exists today but also how quickly risk can be reduced per dollar invested. Key mindset shifts include: From forecasting revenue to mapping technology readiness. From tracking KPIs to testing falsifiable hypotheses. From scaling growth to scaling evidence. 1. Technology and IP — The Foundation of Value The first diligence lens is technical validation. Investors must separate scientific promise from engineering reality. Ask: What has been independently demonstrated, and what remains unproven? Use a Technology Readiness Level (TRL) framework to map progress: TRL 3–5: Lab validation and prototype proof-of-concepts. TRL 6–7: Pilot or limited field trials with defined performance metrics. TRL 8–9: Qualified production systems ready for deployment. Request replicable data, third-party lab results, prototype test reports, and failure analyses. Look for structured experimentation and defined “next proof milestones.” Equally critical is IP defensibility. Strong patent portfolios are not measured by quantity but by claim strength, enforceability, and market coverage. Review patent claims with a freedom-to-operate (FTO) analysis and assess continuation plans. Green flags: independent validation, multiple claims granted, clear continuation strategy.Red flags: single provisional filings, overlapping prior art, or reliance on unprotected trade secrets. 2. Regulatory and Standards Pathway Many deeptech sectors—especially medtech, energy, and advanced materials face heavy regulatory oversight. Evaluate: Applicable standards and certifications (FDA, CE, UL, ISO, ITAR, etc.). Defined testing phases, costs, and lead times. How compliance and certification are budgeted within the funding round. A credible startup presents stage-gated plans, design verification, safety testing, and third-party audits with clear contingency budgets. Failing to anticipate certification hurdles can derail commercialization even when performance is strong. 3. Manufacturing and Supply Chain Deeptech ventures live or die by manufacturing scalability. A prototype in a lab is far from a product on a production line. Focus diligence on: Design for Manufacturability: Has the team engineered around tolerances, yield loss, and cost variability? Supplier validation: Are key materials single-sourced or dual-qualified? Cost curves: Does the company model BOM reduction as a function of volume? Unit economics should improve with scale—not degrade under real-world conditions. Review supplier references, pilot production data, and yield reports, along with contingency plans for critical components. 4. Market Validation and Go-to-Market Strategy Deeptech adoption is slower and more conservative. Market traction is measured by pilots, paid proofs of concept (POCs), and letters of intent (LOIs), not user downloads. Ask: Who are the anchor customers? Are there signed pilots with success metrics? Do successful pilots convert to purchase orders or rollout commitments? Look for evidence of market pull rather than push. Strong startups identify a beachhead market, a narrow, high-value initial use case to expand from once technical and regulatory risks are reduced. 5. Business Model and Unit Economics Deeptech success depends on translating innovation into a sustainable business. Assess: Pricing logic: value-based or cost-plus. Service model: warranty, maintenance, support obligations. Margin progression: gross margin by production lot and expected BOM reductions. Validate a clear path to profitability once production stabilizes. Many deeptech companies underestimate hidden costs tooling, certification renewals, and warranty exposure. Confirm how gross margins evolve with scale and how service costs are managed. 6. Team and Execution Capability Winning deeptech teams blend: Scientific depth (core technology and IP creation). Engineering discipline (system integration, QA, and reliability). Commercial skill (enterprise sales and regulatory navigation). Assess whether the team balances technical and operational expertise, or knows when to bring in external expertise. Signs of execution maturity: Detailed experiment and pilot schedules. Hiring plans tied to risk milestones. Advisors or board members with relevant domain expertise. The best teams demonstrate self-awareness and a plan to close capability gaps as they grow. 7. Financial and Capital Planning In deeptech, capital efficiency equals risk reduction per dollar spent. Each round should connect the capital directly to the risk milestones: Proof of principle → validated prototype. Prototype → regulatory clearance or pilot. Pilot → scaled production or recurring revenue. Ensure the round fully funds the next de-risking event. Partial funding during critical phases, such as certification, can dramatically increase failure risk. Common Red Flags Reliance on anecdotal or non-replicable data. Undefined or unrealistic regulatory timelines. Missing supplier validation for long-lead components. Pilots without success criteria or written commitments. IP limited to provisional filings without FTO analysis. When several appear together, they signal structural risks, not minor gaps. Clear Green Flags Independent third-party validation of test data. Detailed regulatory roadmap with time and budget estimates. Qualified manufacturing partners and early yield data. Paid pilot contracts with expansion pathways. Documented BOM and cost-reduction roadmap. These signals indicate a company transitioning from research to execution, where investors can confidently participate in scaling innovation. Read More from TEN Capital Education here.

    Site Map

    Scroll to Top